Epidemiological Differences in the Impact of COVID-19 Vaccination in the United States and China

• Main Authors: Monia Makhoul, Hiam Chemaitelly, Houssein H. Ayoub, Shaheen Seedat, Laith J. Abu-Raddad
• Format: Article
• Language: English
• Published: MDPI AG 2021-03-01
• Series: Vaccines
• Subjects: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); COVID-19; coronavirus; epidemiology; vaccine; mathematical model
• Online Access: https://www.mdpi.com/2076-393X/9/3/223

This study forecasts Coronavirus Disease 2019 (COVID-19) vaccination impact in two countries at different epidemic phases, the United States (US) and China. We assessed the impact of both a vaccine that prevents infection (<i>VE</i>_S of 95%) and a vaccine that prevents only disease (<i>VE</i>_P of 95%) through mathematical modeling. For <i>VE</i>_S of 95% and gradual easing of restrictions, vaccination in the US reduced the peak incidence of infection, disease, and death by >55% and cumulative incidence by >32% and in China by >77% and >65%, respectively. Nearly three vaccinations were needed to avert one infection in the US, but only one was needed in China. For <i>VE</i>_P of 95%, vaccination benefits were half those for <i>VE</i>_S of 95%. In both countries, impact of vaccination was substantially enhanced with rapid scale-up, vaccine coverage >50%, and slower or no easing of restrictions, particularly in the US. COVID-19 vaccination can flatten, delay, and/or prevent future epidemic waves. However, vaccine impact is destined to be heterogeneous across countries because of an underlying “epidemiologic inequity” that reduces benefits for countries already at high incidence, such as the US. Despite 95% efficacy, actual vaccine impact could be meager in such countries if vaccine scale-up is slow, acceptance is poor, or restrictions are eased prematurely.